Wall Street brokerages expect The Joint Corp. (NASDAQ:JYNT) to report $21.61 million in sales for the current quarter, according to Zacks. Two analysts have issued estimates for Joint’s earnings. The lowest sales estimate is $21.42 million and the highest is $21.80 million. Joint posted sales of $17.04 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 26.8%. The business is expected to report its next earnings results on Thursday, March 3rd.
On average, analysts expect that Joint will report full year sales of $80.39 million for the current fiscal year, with estimates ranging from $80.18 million to $80.60 million. For the next year, analysts anticipate that the firm will post sales of $102.26 million, with estimates ranging from $100.52 million to $104.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that follow Joint.
Joint (NASDAQ:JYNT) last issued its quarterly earnings data on Thursday, November 4th. The company reported $0.13 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.04 by $0.09. Joint had a net margin of 23.18% and a return on equity of 34.65%. During the same period last year, the firm posted $0.11 earnings per share.
JYNT stock traded down $1.18 during trading on Thursday, reaching $83.49. The company had a trading volume of 97,610 shares, compared to its average volume of 213,464. Joint has a 52 week low of $24.60 and a 52 week high of $111.06. The business has a 50 day moving average of $92.08 and a 200 day moving average of $85.39. The company has a market cap of $1.20 billion, a P/E ratio of 70.16 and a beta of 1.18.
In other Joint news, CFO Jake Singleton sold 2,614 shares of the stock in a transaction dated Wednesday, September 1st. The stock was sold at an average price of $103.12, for a total value of $269,555.68. Following the transaction, the chief financial officer now owns 7,734 shares of the company’s stock, valued at $797,530.08. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Ronald V. Davella sold 20,000 shares of the company’s stock in a transaction on Monday, September 13th. The stock was sold at an average price of $101.18, for a total value of $2,023,600.00. The disclosure for this sale can be found here. 4.60% of the stock is owned by insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in JYNT. BlackRock Inc. increased its holdings in Joint by 100.9% in the 2nd quarter. BlackRock Inc. now owns 2,014,162 shares of the company’s stock valued at $169,028,000 after acquiring an additional 1,011,690 shares during the last quarter. Invesco Ltd. grew its position in shares of Joint by 472.2% during the second quarter. Invesco Ltd. now owns 298,943 shares of the company’s stock valued at $25,087,000 after purchasing an additional 246,694 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Joint by 36.9% during the second quarter. Vanguard Group Inc. now owns 908,786 shares of the company’s stock valued at $76,265,000 after purchasing an additional 245,124 shares in the last quarter. State Street Corp increased its holdings in shares of Joint by 84.0% in the second quarter. State Street Corp now owns 430,963 shares of the company’s stock worth $36,166,000 after purchasing an additional 196,735 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in shares of Joint by 54.9% in the second quarter. Dimensional Fund Advisors LP now owns 258,093 shares of the company’s stock worth $21,659,000 after buying an additional 91,447 shares in the last quarter. 88.98% of the stock is owned by institutional investors and hedge funds.
Joint Company Profile
The Joint Corp. (United States) engages in the development, ownership, operation, support and management of chiropractic clinics. It operates through two segments: Corporate Clinics and Franchise Operations. The Corporate Clinics segment comprises of the operating activities of the company owned or managed clinics.
Further Reading: What is insider trading?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Joint Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Joint and related companies with MarketBeat.com's FREE daily email newsletter.